升麻治疗乙型病毒性肝炎的活性部位筛选

目的: 筛选升麻药材中治疗乙型病毒性肝炎的药用活性部位。 方法: 采用树脂分离技术,制备升麻总酚酸、总皂苷部位,并以拉米夫定为阳性药,选择HBV转基因小鼠作为受试动物,以小鼠血清中HBsAg及HBeAg为指标;以HepG2-2.2.15细胞株为模型,检测细胞内核心颗粒HBV DNA的变化,考察升麻水提液、总酚酸、总皂苷、升麻苷及阿魏酸5个组分对HBsAg及HBeAg的影响。 结果: 5个组别对小鼠血清中HBsAg及HBeAg均有一定的降低作用,且总酚酸显著降低HBsAg及HBeAg,与对照组有显著性差异(P<0.01),且阿魏酸是其中的有效成分;总皂苷可以降低HBsAg,与对照组有较显著性差异(P<0.05),但是升麻苷对HBsAg及HBeAg的作用均无显著性差异;升麻总酚酸能明显降低HepG2-2.2.15细胞胞浆核心颗粒HBV DNA水平(P<0.01)。 结论: 升麻中的总酚酸部位是其治疗乙型病毒性肝炎的药用活性部位,本研究为治疗乙型病毒性肝炎的药物开发提供了数据参考。

Screeningof Potent Active Components of Cimicifugae Rhizoma for Treating Hepatitis B Virus

Objective: To study the potent active components of Cimicifugae Rhizoma for treating hepatitis B virus(HBV). Method: The total phenolic acid and saponins of Cimicifugae Rhizoma were separated by macroporous resin, HBV DNA, HBsAg and HBeAg were observed to analyze the anti-hepatitis B virus effect of prim-o-glucosylcimifugin, ferulic acid, Cimicifugae Rhizoma aqueous extract solution, Cimicifugae Rhizoma phenolic acid and Cimicifugae Rhizoma saponins. Result: The five groups significantly reduced the concentration of HBsAg and HBeAg. Compared with the blank control group, the total phenolic acid can decrease the HBsAg and HBeAg (P<0.01) and the ferulic acid was the potential active component, Cimicifugae Rhizoma saponins can reduce the HBsAg (P<0.05) but prim-o-glucosylcimifugin have no obvious anti-hepatitis B virus effect. The total phenolic acid of Cimicifugae Rhizoma can remarkably decrease the level of viral core associated-HBV DNA in the cytoplasm. Conclusion: The total phenolic acid of Cimicifugae Rhizoma is the active part to anti-hepatitis B virus effect, and the results provide the basis of screening new drugs for treatment hepatitis B virus.